CA2497569C - 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound - Google Patents
2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound Download PDFInfo
- Publication number
- CA2497569C CA2497569C CA2497569A CA2497569A CA2497569C CA 2497569 C CA2497569 C CA 2497569C CA 2497569 A CA2497569 A CA 2497569A CA 2497569 A CA2497569 A CA 2497569A CA 2497569 C CA2497569 C CA 2497569C
- Authority
- CA
- Canada
- Prior art keywords
- group
- substituted
- halogen
- unsubstituted
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound Chemical class 0.000 title claims abstract description 2992
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 870
- 150000001875 compounds Chemical class 0.000 claims abstract description 126
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 94
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 50
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 45
- 125000003003 spiro group Chemical group 0.000 claims abstract description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 1147
- 125000005843 halogen group Chemical group 0.000 claims description 571
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 454
- 125000001424 substituent group Chemical group 0.000 claims description 241
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 192
- 125000000217 alkyl group Chemical group 0.000 claims description 188
- 150000003839 salts Chemical class 0.000 claims description 167
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 93
- 125000003545 alkoxy group Chemical group 0.000 claims description 86
- 125000003277 amino group Chemical group 0.000 claims description 84
- 125000002252 acyl group Chemical group 0.000 claims description 76
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 57
- 125000004043 oxo group Chemical group O=* 0.000 claims description 57
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 54
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 51
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 50
- 125000004193 piperazinyl group Chemical group 0.000 claims description 42
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 125000003386 piperidinyl group Chemical group 0.000 claims description 34
- 125000004076 pyridyl group Chemical group 0.000 claims description 32
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 31
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 24
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 22
- 125000002971 oxazolyl group Chemical group 0.000 claims description 22
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 21
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 21
- 125000002883 imidazolyl group Chemical group 0.000 claims description 20
- 125000005936 piperidyl group Chemical group 0.000 claims description 20
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 19
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 17
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000001624 naphthyl group Chemical group 0.000 claims description 16
- 201000008827 tuberculosis Diseases 0.000 claims description 16
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 14
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 14
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 14
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 14
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 13
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical group C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 10
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 10
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 10
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 10
- 239000000814 tuberculostatic agent Substances 0.000 claims description 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 9
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 claims description 9
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 8
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 8
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 claims description 8
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 8
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims description 8
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 8
- 125000006678 phenoxycarbonyl group Chemical group 0.000 claims description 8
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims description 7
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 7
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical group C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 6
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 125000004423 acyloxy group Chemical group 0.000 claims description 6
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical group C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000005493 quinolyl group Chemical group 0.000 claims description 6
- 238000006798 ring closing metathesis reaction Methods 0.000 claims description 6
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 5
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims description 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 5
- XDAOLTSRNUSPPH-XMMPIXPASA-N delamanid Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 XDAOLTSRNUSPPH-XMMPIXPASA-N 0.000 claims description 5
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims description 4
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims description 4
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 4
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 4
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical group C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 claims description 4
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical group C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 102220473072 Chemerin-like receptor 2_R14Q_mutation Human genes 0.000 claims description 4
- JJHHIJFTHRNPIK-UHFFFAOYSA-N Diphenyl sulfoxide Chemical compound C=1C=CC=CC=1S(=O)C1=CC=CC=C1 JJHHIJFTHRNPIK-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 125000001118 alkylidene group Chemical group 0.000 claims description 4
- 125000005225 alkynyloxycarbonyl group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 claims description 4
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000005504 styryl group Chemical group 0.000 claims description 4
- 229930192474 thiophene Natural products 0.000 claims description 4
- 125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 claims description 3
- AIUOUEPKBRDPLG-UHFFFAOYSA-N 1,3-benzoxathiole Chemical group C1=CC=C2SCOC2=C1 AIUOUEPKBRDPLG-UHFFFAOYSA-N 0.000 claims description 3
- YBSBINDRCMOTTG-FQEVSTJZSA-N FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)C[C@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 Chemical compound FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)C[C@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 YBSBINDRCMOTTG-FQEVSTJZSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 3
- 125000005554 pyridyloxy group Chemical group 0.000 claims description 3
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 3
- FIYNYEBSXNUVMP-QGZVFWFLSA-N (2r)-2-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1C1=CC=C(Cl)C=C1 FIYNYEBSXNUVMP-QGZVFWFLSA-N 0.000 claims description 2
- IBYBLYXYIMYXLC-RUZDIDTESA-N (2r)-2-[[4-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1C(CC1)CCN1CC1=CC=C(Cl)C=C1 IBYBLYXYIMYXLC-RUZDIDTESA-N 0.000 claims description 2
- AKNCGQAEIOXCDV-XMMPIXPASA-N (2r)-2-[[4-[4-(4-chlorophenoxy)piperidin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(Cl)C=C1 AKNCGQAEIOXCDV-XMMPIXPASA-N 0.000 claims description 2
- LYOIGYXSILNCGD-HSZRJFAPSA-N (2r)-2-[[4-[4-(4-chlorophenyl)piperazin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1C1=CC=C(Cl)C=C1 LYOIGYXSILNCGD-HSZRJFAPSA-N 0.000 claims description 2
- GFILILIJROUKQX-XMMPIXPASA-N (2r)-2-[[4-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(Cl)C=C1 GFILILIJROUKQX-XMMPIXPASA-N 0.000 claims description 2
- LXWLEHKPRBDYGL-GOSISDBHSA-N (2r)-2-methyl-6-nitro-2-[[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 LXWLEHKPRBDYGL-GOSISDBHSA-N 0.000 claims description 2
- LWBIDBQNZCECSS-QGZVFWFLSA-N (2r)-2-methyl-6-nitro-2-[[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1C1=CC=C(OC(F)(F)F)C=C1 LWBIDBQNZCECSS-QGZVFWFLSA-N 0.000 claims description 2
- AWDXPROPYRAKLT-GOSISDBHSA-N (2r)-2-methyl-6-nitro-2-[[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCC1OC1=CC=C(C(F)(F)F)C=C1 AWDXPROPYRAKLT-GOSISDBHSA-N 0.000 claims description 2
- QJIFSMDAAMROGJ-QGZVFWFLSA-N (2r)-2-methyl-6-nitro-2-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 QJIFSMDAAMROGJ-QGZVFWFLSA-N 0.000 claims description 2
- DMAIXEPFPJEFMX-XMMPIXPASA-N (2r)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(C(F)(F)F)C=C1 DMAIXEPFPJEFMX-XMMPIXPASA-N 0.000 claims description 2
- ZMQUUTLDDPXMNF-HSZRJFAPSA-N (2r)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 ZMQUUTLDDPXMNF-HSZRJFAPSA-N 0.000 claims description 2
- GZEWSZWWEUTZIP-XMMPIXPASA-N (2r)-2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethoxy)phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(OC(F)(F)F)C=C1 GZEWSZWWEUTZIP-XMMPIXPASA-N 0.000 claims description 2
- JMBCEUCFQUVBIJ-XMMPIXPASA-N (2r)-2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(C(F)(F)F)C=C1 JMBCEUCFQUVBIJ-XMMPIXPASA-N 0.000 claims description 2
- VVIPVTJEVUGSRO-XMMPIXPASA-N (2r)-2-methyl-6-nitro-2-[[4-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 VVIPVTJEVUGSRO-XMMPIXPASA-N 0.000 claims description 2
- UCWWPISVZMWAJC-OAQYLSRUSA-N (2r)-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole Chemical compound C([C@H]1CN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 UCWWPISVZMWAJC-OAQYLSRUSA-N 0.000 claims description 2
- FIYNYEBSXNUVMP-KRWDZBQOSA-N (2s)-2-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1C1=CC=C(Cl)C=C1 FIYNYEBSXNUVMP-KRWDZBQOSA-N 0.000 claims description 2
- IBYBLYXYIMYXLC-VWLOTQADSA-N (2s)-2-[[4-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1C(CC1)CCN1CC1=CC=C(Cl)C=C1 IBYBLYXYIMYXLC-VWLOTQADSA-N 0.000 claims description 2
- AKNCGQAEIOXCDV-DEOSSOPVSA-N (2s)-2-[[4-[4-(4-chlorophenoxy)piperidin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(Cl)C=C1 AKNCGQAEIOXCDV-DEOSSOPVSA-N 0.000 claims description 2
- LYOIGYXSILNCGD-QHCPKHFHSA-N (2s)-2-[[4-[4-(4-chlorophenyl)piperazin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1C1=CC=C(Cl)C=C1 LYOIGYXSILNCGD-QHCPKHFHSA-N 0.000 claims description 2
- GFILILIJROUKQX-DEOSSOPVSA-N (2s)-2-[[4-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(Cl)C=C1 GFILILIJROUKQX-DEOSSOPVSA-N 0.000 claims description 2
- LXWLEHKPRBDYGL-SFHVURJKSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 LXWLEHKPRBDYGL-SFHVURJKSA-N 0.000 claims description 2
- LWBIDBQNZCECSS-KRWDZBQOSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1C1=CC=C(OC(F)(F)F)C=C1 LWBIDBQNZCECSS-KRWDZBQOSA-N 0.000 claims description 2
- AWDXPROPYRAKLT-SFHVURJKSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCC1OC1=CC=C(C(F)(F)F)C=C1 AWDXPROPYRAKLT-SFHVURJKSA-N 0.000 claims description 2
- QJIFSMDAAMROGJ-KRWDZBQOSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 QJIFSMDAAMROGJ-KRWDZBQOSA-N 0.000 claims description 2
- XDAOLTSRNUSPPH-DEOSSOPVSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 XDAOLTSRNUSPPH-DEOSSOPVSA-N 0.000 claims description 2
- DMAIXEPFPJEFMX-DEOSSOPVSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(C(F)(F)F)C=C1 DMAIXEPFPJEFMX-DEOSSOPVSA-N 0.000 claims description 2
- ZMQUUTLDDPXMNF-QHCPKHFHSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 ZMQUUTLDDPXMNF-QHCPKHFHSA-N 0.000 claims description 2
- GZEWSZWWEUTZIP-DEOSSOPVSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethoxy)phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(OC(F)(F)F)C=C1 GZEWSZWWEUTZIP-DEOSSOPVSA-N 0.000 claims description 2
- JMBCEUCFQUVBIJ-DEOSSOPVSA-N (2s)-2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(C(F)(F)F)C=C1 JMBCEUCFQUVBIJ-DEOSSOPVSA-N 0.000 claims description 2
- VVIPVTJEVUGSRO-DEOSSOPVSA-N (2s)-2-methyl-6-nitro-2-[[4-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 VVIPVTJEVUGSRO-DEOSSOPVSA-N 0.000 claims description 2
- UCWWPISVZMWAJC-NRFANRHFSA-N (2s)-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole Chemical compound C([C@@H]1CN2C=C(N=C2O1)[N+](=O)[O-])OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 UCWWPISVZMWAJC-NRFANRHFSA-N 0.000 claims description 2
- KLYOKTHRMAYFJG-UHFFFAOYSA-N (3,4-dichlorophenyl)methyl 4-[4-[(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)methoxy]phenyl]piperazine-1-carboxylate Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCN1C(=O)OCC1=CC=C(Cl)C(Cl)=C1 KLYOKTHRMAYFJG-UHFFFAOYSA-N 0.000 claims description 2
- KLYOKTHRMAYFJG-RUZDIDTESA-N (3,4-dichlorophenyl)methyl 4-[4-[[(2r)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]methoxy]phenyl]piperazine-1-carboxylate Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1C(=O)OCC1=CC=C(Cl)C(Cl)=C1 KLYOKTHRMAYFJG-RUZDIDTESA-N 0.000 claims description 2
- KLYOKTHRMAYFJG-VWLOTQADSA-N (3,4-dichlorophenyl)methyl 4-[4-[[(2s)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]methoxy]phenyl]piperazine-1-carboxylate Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1C(=O)OCC1=CC=C(Cl)C(Cl)=C1 KLYOKTHRMAYFJG-VWLOTQADSA-N 0.000 claims description 2
- 125000004844 (C1-C6) alkoxyimino group Chemical group 0.000 claims description 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims description 2
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical group C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 claims description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical group C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims description 2
- 125000005943 1,2,3,6-tetrahydropyridyl group Chemical group 0.000 claims description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical group C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 2
- FDUVAPUGTURJLJ-UHFFFAOYSA-N 1,4-dioxa-2-azaspiro[4.5]decane Chemical group O1CNOC11CCCCC1 FDUVAPUGTURJLJ-UHFFFAOYSA-N 0.000 claims description 2
- WOHLSTOWRAOMSG-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole Chemical group C1=CC=C2SCNC2=C1 WOHLSTOWRAOMSG-UHFFFAOYSA-N 0.000 claims description 2
- HRCMXYXVAWHBTH-UHFFFAOYSA-N 2,3-dihydro-1,3-benzoxazole Chemical group C1=CC=C2OCNC2=C1 HRCMXYXVAWHBTH-UHFFFAOYSA-N 0.000 claims description 2
- DYXWBIIIQALDGP-UHFFFAOYSA-N 2,4-dihydro-1h-3,1-benzoxazine Chemical group C1=CC=C2COCNC2=C1 DYXWBIIIQALDGP-UHFFFAOYSA-N 0.000 claims description 2
- FIYNYEBSXNUVMP-UHFFFAOYSA-N 2-[[4-(4-chlorophenyl)piperazin-1-yl]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)CN(CC1)CCN1C1=CC=C(Cl)C=C1 FIYNYEBSXNUVMP-UHFFFAOYSA-N 0.000 claims description 2
- IBYBLYXYIMYXLC-UHFFFAOYSA-N 2-[[4-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1C(CC1)CCN1CC1=CC=C(Cl)C=C1 IBYBLYXYIMYXLC-UHFFFAOYSA-N 0.000 claims description 2
- AKNCGQAEIOXCDV-UHFFFAOYSA-N 2-[[4-[4-(4-chlorophenoxy)piperidin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(Cl)C=C1 AKNCGQAEIOXCDV-UHFFFAOYSA-N 0.000 claims description 2
- LYOIGYXSILNCGD-UHFFFAOYSA-N 2-[[4-[4-(4-chlorophenyl)piperazin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCN1C1=CC=C(Cl)C=C1 LYOIGYXSILNCGD-UHFFFAOYSA-N 0.000 claims description 2
- GFILILIJROUKQX-UHFFFAOYSA-N 2-[[4-[4-[(4-chlorophenyl)methyl]piperazin-1-yl]phenoxy]methyl]-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(Cl)C=C1 GFILILIJROUKQX-UHFFFAOYSA-N 0.000 claims description 2
- YKTNEBRVZQRHBY-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[3-[4-(trifluoromethoxy)phenoxy]-8-azabicyclo[3.2.1]octan-8-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N1C(C2)CCC1CC2OC1=CC=C(OC(F)(F)F)C=C1 YKTNEBRVZQRHBY-UHFFFAOYSA-N 0.000 claims description 2
- LXWLEHKPRBDYGL-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)CN(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 LXWLEHKPRBDYGL-UHFFFAOYSA-N 0.000 claims description 2
- LWBIDBQNZCECSS-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-(trifluoromethoxy)phenyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)CN(CC1)CCN1C1=CC=C(OC(F)(F)F)C=C1 LWBIDBQNZCECSS-UHFFFAOYSA-N 0.000 claims description 2
- AWDXPROPYRAKLT-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)CN(CC1)CCC1OC1=CC=C(C(F)(F)F)C=C1 AWDXPROPYRAKLT-UHFFFAOYSA-N 0.000 claims description 2
- QJIFSMDAAMROGJ-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)CN(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 QJIFSMDAAMROGJ-UHFFFAOYSA-N 0.000 claims description 2
- XDAOLTSRNUSPPH-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 XDAOLTSRNUSPPH-UHFFFAOYSA-N 0.000 claims description 2
- DMAIXEPFPJEFMX-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethyl)phenoxy]piperidin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(C(F)(F)F)C=C1 DMAIXEPFPJEFMX-UHFFFAOYSA-N 0.000 claims description 2
- GZEWSZWWEUTZIP-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethoxy)phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(OC(F)(F)F)C=C1 GZEWSZWWEUTZIP-UHFFFAOYSA-N 0.000 claims description 2
- JMBCEUCFQUVBIJ-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-[[4-(trifluoromethyl)phenyl]methyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCN1CC1=CC=C(C(F)(F)F)C=C1 JMBCEUCFQUVBIJ-UHFFFAOYSA-N 0.000 claims description 2
- VVIPVTJEVUGSRO-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[[4-[4-(trifluoromethyl)phenyl]phenyl]methyl]piperazin-1-yl]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)CN(CC1)CCN1CC(C=C1)=CC=C1C1=CC=C(C(F)(F)F)C=C1 VVIPVTJEVUGSRO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 claims description 2
- JKNSMBZZZFGYCB-UHFFFAOYSA-N 4,5-dihydrooxadiazole Chemical group C1CN=NO1 JKNSMBZZZFGYCB-UHFFFAOYSA-N 0.000 claims description 2
- UCWWPISVZMWAJC-UHFFFAOYSA-N 6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl]phenoxy]methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole Chemical compound O1C2=NC([N+](=O)[O-])=CN2CC1COC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 UCWWPISVZMWAJC-UHFFFAOYSA-N 0.000 claims description 2
- DGGKXQQCVPAUEA-UHFFFAOYSA-N 8-azabicyclo[3.2.1]octane Chemical group C1CCC2CCC1N2 DGGKXQQCVPAUEA-UHFFFAOYSA-N 0.000 claims description 2
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical group C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 claims description 2
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 239000004593 Epoxy Substances 0.000 claims description 2
- YBSBINDRCMOTTG-HXUWFJFHSA-N FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)C[C@@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 Chemical compound FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)C[C@@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 YBSBINDRCMOTTG-HXUWFJFHSA-N 0.000 claims description 2
- TXRSPJFTVZSLCH-HXUWFJFHSA-N FC(F)(F)OC1=CC=C2OC(C=NN3CCN(CC3)C[C@@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 Chemical compound FC(F)(F)OC1=CC=C2OC(C=NN3CCN(CC3)C[C@@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 TXRSPJFTVZSLCH-HXUWFJFHSA-N 0.000 claims description 2
- TXRSPJFTVZSLCH-FQEVSTJZSA-N FC(F)(F)OC1=CC=C2OC(C=NN3CCN(CC3)C[C@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 Chemical compound FC(F)(F)OC1=CC=C2OC(C=NN3CCN(CC3)C[C@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 TXRSPJFTVZSLCH-FQEVSTJZSA-N 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- ZQJDWBXBOUAVET-RUZDIDTESA-N [4-(trifluoromethoxy)phenyl]methyl 4-[4-[[(2r)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]methoxy]phenyl]piperazine-1-carboxylate Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1C(=O)OCC1=CC=C(OC(F)(F)F)C=C1 ZQJDWBXBOUAVET-RUZDIDTESA-N 0.000 claims description 2
- ZQJDWBXBOUAVET-VWLOTQADSA-N [4-(trifluoromethoxy)phenyl]methyl 4-[4-[[(2s)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]methoxy]phenyl]piperazine-1-carboxylate Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCN1C(=O)OCC1=CC=C(OC(F)(F)F)C=C1 ZQJDWBXBOUAVET-VWLOTQADSA-N 0.000 claims description 2
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical group C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical group C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 claims description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005948 methanesulfonyloxy group Chemical group 0.000 claims description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 2
- YBSBINDRCMOTTG-UHFFFAOYSA-N n-[4-[(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)methyl]piperazin-1-yl]-1-[5-(trifluoromethyl)-1-benzofuran-2-yl]methanimine Chemical compound FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)CC3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 YBSBINDRCMOTTG-UHFFFAOYSA-N 0.000 claims description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000005543 phthalimide group Chemical group 0.000 claims description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 2
- 125000001725 pyrenyl group Chemical group 0.000 claims description 2
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical group O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 2
- 150000003536 tetrazoles Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 1
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims 1
- GCLWAJFSWVDEOD-UHFFFAOYSA-N 1-(5-chloro-1-benzofuran-2-yl)-n-[4-[(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)methyl]piperazin-1-yl]methanimine Chemical compound ClC1=CC=C2OC(C=NN3CCN(CC3)CC3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 GCLWAJFSWVDEOD-UHFFFAOYSA-N 0.000 claims 1
- GCLWAJFSWVDEOD-FQEVSTJZSA-N 1-(5-chloro-1-benzofuran-2-yl)-n-[4-[[(2s)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]methyl]piperazin-1-yl]methanimine Chemical compound ClC1=CC=C2OC(C=NN3CCN(CC3)C[C@]3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 GCLWAJFSWVDEOD-FQEVSTJZSA-N 0.000 claims 1
- ZMQUUTLDDPXMNF-UHFFFAOYSA-N 2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 ZMQUUTLDDPXMNF-UHFFFAOYSA-N 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- PBHHVJAUXOFMRE-UHFFFAOYSA-N n-[4-[(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)methyl]piperazin-1-yl]-1-[4-(trifluoromethyl)phenyl]methanimine Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)CN(CC1)CCN1N=CC1=CC=C(C(F)(F)F)C=C1 PBHHVJAUXOFMRE-UHFFFAOYSA-N 0.000 claims 1
- PBHHVJAUXOFMRE-SFHVURJKSA-N n-[4-[[(2s)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]methyl]piperazin-1-yl]-1-[4-(trifluoromethyl)phenyl]methanimine Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1N=CC1=CC=C(C(F)(F)F)C=C1 PBHHVJAUXOFMRE-SFHVURJKSA-N 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 abstract description 24
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 11
- 241000894006 Bacteria Species 0.000 abstract description 10
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 16
- RFEBDZANCVHDLP-UHFFFAOYSA-N 3-[(4-cyanophenyl)methylamino]-6-(trifluoromethyl)quinoxaline-2-carboxylic acid Chemical compound OC(=O)C1=NC2=CC=C(C(F)(F)F)C=C2N=C1NCC1=CC=C(C#N)C=C1 RFEBDZANCVHDLP-UHFFFAOYSA-N 0.000 description 8
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 5
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 5
- 229960001225 rifampicin Drugs 0.000 description 5
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 4
- 125000006499 2-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 125000006494 2-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 4
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 4
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000006500 3-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC(F)(F)F)=C1[H])C([H])([H])* 0.000 description 4
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 4
- 125000000173 4-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC(F)(F)F)C([H])([H])* 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229960000285 ethambutol Drugs 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 229960003350 isoniazid Drugs 0.000 description 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 4
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 4
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 4
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 3
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 3
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 3
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 3
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 3
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 3
- 125000005917 3-methylpentyl group Chemical group 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 3
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 description 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000006204 1-benzoyl ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(=O)C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- 125000006507 2,4-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(F)C(=C1[H])C([H])([H])* 0.000 description 2
- 125000006183 2,4-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])*)C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000006184 2,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C(=C1[H])C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 2
- 125000006197 2-benzoyl ethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(=O)C([H])([H])C([H])([H])* 0.000 description 2
- 125000006280 2-bromobenzyl group Chemical group [H]C1=C([H])C(Br)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 2
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000006481 2-iodobenzyl group Chemical group [H]C1=C([H])C(I)=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 2
- 125000006511 3,4,5-trifluorobenzyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1C([H])([H])* 0.000 description 2
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 2
- 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 2
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 2
- 125000006186 3,5-dimethyl benzyl group Chemical group [H]C1=C(C([H])=C(C([H])=C1C([H])([H])[H])C([H])([H])*)C([H])([H])[H] 0.000 description 2
- 125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 2
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 description 2
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 2
- 125000006482 3-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(I)=C1[H])C([H])([H])* 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 2
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 2
- 125000006483 4-iodobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1I)C([H])([H])* 0.000 description 2
- 125000002528 4-isopropyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 241000186365 Mycobacterium fortuitum Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000005997 bromomethyl group Chemical group 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 2
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 125000006606 n-butoxy group Chemical group 0.000 description 2
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000005484 neopentoxy group Chemical group 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 229960005206 pyrazinamide Drugs 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- 125000005920 sec-butoxy group Chemical group 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- YKTNEBRVZQRHBY-AMOIIXHWSA-N (2r)-2-methyl-6-nitro-2-[[4-[3-[4-(trifluoromethoxy)phenoxy]-8-azabicyclo[3.2.1]octan-8-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N1C(C2)CCC1CC2OC1=CC=C(OC(F)(F)F)C=C1 YKTNEBRVZQRHBY-AMOIIXHWSA-N 0.000 description 1
- OGZYKVAFRSEKTB-VWLOTQADSA-N (2s)-2-methyl-6-nitro-2-[[4-[1-[[4-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1C(CC1)CCN1CC1=CC=C(OC(F)(F)F)C=C1 OGZYKVAFRSEKTB-VWLOTQADSA-N 0.000 description 1
- YKTNEBRVZQRHBY-NYJDFHIHSA-N (2s)-2-methyl-6-nitro-2-[[4-[3-[4-(trifluoromethoxy)phenoxy]-8-azabicyclo[3.2.1]octan-8-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N1C(C2)CCC1CC2OC1=CC=C(OC(F)(F)F)C=C1 YKTNEBRVZQRHBY-NYJDFHIHSA-N 0.000 description 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
- XMTMHZRIDYVRTH-UHFFFAOYSA-N 1-(5-chloro-1-benzofuran-2-yl)-n-[4-(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)piperazin-1-yl]methanimine Chemical compound ClC1=CC=C2OC(C=NN3CCN(CC3)C3(OC4=NC(=CN4C3)[N+]([O-])=O)C)=CC2=C1 XMTMHZRIDYVRTH-UHFFFAOYSA-N 0.000 description 1
- XMTMHZRIDYVRTH-LJQANCHMSA-N 1-(5-chloro-1-benzofuran-2-yl)-n-[4-[(2r)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]piperazin-1-yl]methanimine Chemical compound ClC1=CC=C2OC(C=NN3CCN(CC3)[C@@]3(OC4=NC(=CN4C3)[N+]([O-])=O)C)=CC2=C1 XMTMHZRIDYVRTH-LJQANCHMSA-N 0.000 description 1
- XMTMHZRIDYVRTH-IBGZPJMESA-N 1-(5-chloro-1-benzofuran-2-yl)-n-[4-[(2s)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]piperazin-1-yl]methanimine Chemical compound ClC1=CC=C2OC(C=NN3CCN(CC3)[C@]3(OC4=NC(=CN4C3)[N+]([O-])=O)C)=CC2=C1 XMTMHZRIDYVRTH-IBGZPJMESA-N 0.000 description 1
- WGUXTQDCAZNJIF-UHFFFAOYSA-N 1-methyl-3,5-bis(trifluoromethyl)benzene Chemical group CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGUXTQDCAZNJIF-UHFFFAOYSA-N 0.000 description 1
- 125000005978 1-naphthyloxy group Chemical group 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 description 1
- 125000006012 2-chloroethoxy group Chemical group 0.000 description 1
- 125000002379 2-iodobenzoyl group Chemical group IC1=C(C(=O)*)C=CC=C1 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000005979 2-naphthyloxy group Chemical group 0.000 description 1
- 125000000850 2H-chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- MGZFQOJHXCVYBP-UHFFFAOYSA-N 3-[4-(trifluoromethyl)phenyl]prop-2-enyl 4-[(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)methyl]piperazine-1-carboxylate Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)CN(CC1)CCN1C(=O)OCC=CC1=CC=C(C(F)(F)F)C=C1 MGZFQOJHXCVYBP-UHFFFAOYSA-N 0.000 description 1
- MGZFQOJHXCVYBP-OAQYLSRUSA-N 3-[4-(trifluoromethyl)phenyl]prop-2-enyl 4-[[(2R)-2-methyl-6-nitro-3H-imidazo[2,1-b][1,3]oxazol-2-yl]methyl]piperazine-1-carboxylate Chemical compound C([C@@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)N(CC1)CCN1C(=O)OCC=CC1=CC=C(C(F)(F)F)C=C1 MGZFQOJHXCVYBP-OAQYLSRUSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- 125000002672 4-bromobenzoyl group Chemical group BrC1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- RTWPOMOFGYHVAF-GZNOUCQFSA-N 4-methylbenzenesulfonic acid;(2r)-2-methyl-6-nitro-2-[[4-[3-[4-(trifluoromethoxy)phenoxy]-8-azabicyclo[3.2.1]octan-8-yl]phenoxy]methyl]-3h-imidazo[2,1-b][1,3]oxazole Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N1C(C2)CCC1CC2OC1=CC=C(OC(F)(F)F)C=C1 RTWPOMOFGYHVAF-GZNOUCQFSA-N 0.000 description 1
- VPAPSEYKVPULKR-UHFFFAOYSA-N 6-[3-(trifluoromethyl)phenyl]pyridine-3-carboxylic acid Chemical group N1=CC(C(=O)O)=CC=C1C1=CC=CC(C(F)(F)F)=C1 VPAPSEYKVPULKR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000033126 Colobomatous microphthalmia Diseases 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QQWSBGZHRATVJN-LJQANCHMSA-N FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)[C@@]3(OC4=NC(=CN4C3)[N+]([O-])=O)C)=CC2=C1 Chemical compound FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)[C@@]3(OC4=NC(=CN4C3)[N+]([O-])=O)C)=CC2=C1 QQWSBGZHRATVJN-LJQANCHMSA-N 0.000 description 1
- QQWSBGZHRATVJN-IBGZPJMESA-N FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)[C@]3(OC4=NC(=CN4C3)[N+]([O-])=O)C)=CC2=C1 Chemical compound FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)[C@]3(OC4=NC(=CN4C3)[N+]([O-])=O)C)=CC2=C1 QQWSBGZHRATVJN-IBGZPJMESA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000187473 Mycobacterium aurum Species 0.000 description 1
- 241000545499 Mycobacterium avium-intracellulare Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241001147828 Mycobacterium haemophilum Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187493 Mycobacterium malmoense Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 241001147832 Mycobacterium shimoidei Species 0.000 description 1
- 241000187489 Mycobacterium simiae Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187496 Mycobacterium szulgai Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- ZQJDWBXBOUAVET-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]methyl 4-[4-[(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)methoxy]phenyl]piperazine-1-carboxylate Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)COC(C=C1)=CC=C1N(CC1)CCN1C(=O)OCC1=CC=C(OC(F)(F)F)C=C1 ZQJDWBXBOUAVET-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000000676 alkoxyimino group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000006015 bromomethoxy group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000004651 chloromethoxy group Chemical group ClCO* 0.000 description 1
- 208000014826 cranial nerve neuropathy Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004788 dichlorofluoromethoxy group Chemical group ClC(O*)(F)Cl 0.000 description 1
- 125000004783 dichloromethoxy group Chemical group ClC(O*)Cl 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 208000034367 isolated with coloboma microphthalmia Diseases 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001064 morpholinomethyl group Chemical group [H]C([H])(*)N1C([H])([H])C([H])([H])OC([H])([H])C1([H])[H] 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- NTTYISLFBKCWJN-UHFFFAOYSA-N n-[4-(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)piperazin-1-yl]-1-[4-(trifluoromethyl)phenyl]methanimine Chemical compound C1N2C=C([N+]([O-])=O)N=C2OC1(C)N(CC1)CCN1N=CC1=CC=C(C(F)(F)F)C=C1 NTTYISLFBKCWJN-UHFFFAOYSA-N 0.000 description 1
- QQWSBGZHRATVJN-UHFFFAOYSA-N n-[4-(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)piperazin-1-yl]-1-[5-(trifluoromethyl)-1-benzofuran-2-yl]methanimine Chemical compound FC(F)(F)C1=CC=C2OC(C=NN3CCN(CC3)C3(OC4=NC(=CN4C3)[N+]([O-])=O)C)=CC2=C1 QQWSBGZHRATVJN-UHFFFAOYSA-N 0.000 description 1
- TXRSPJFTVZSLCH-UHFFFAOYSA-N n-[4-[(2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl)methyl]piperazin-1-yl]-1-[5-(trifluoromethoxy)-1-benzofuran-2-yl]methanimine Chemical compound FC(F)(F)OC1=CC=C2OC(C=NN3CCN(CC3)CC3(C)OC4=NC(=CN4C3)[N+]([O-])=O)=CC2=C1 TXRSPJFTVZSLCH-UHFFFAOYSA-N 0.000 description 1
- NTTYISLFBKCWJN-QGZVFWFLSA-N n-[4-[(2r)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]piperazin-1-yl]-1-[4-(trifluoromethyl)phenyl]methanimine Chemical compound C1CN([C@@]2(OC3=NC(=CN3C2)[N+]([O-])=O)C)CCN1N=CC1=CC=C(C(F)(F)F)C=C1 NTTYISLFBKCWJN-QGZVFWFLSA-N 0.000 description 1
- NTTYISLFBKCWJN-KRWDZBQOSA-N n-[4-[(2s)-2-methyl-6-nitro-3h-imidazo[2,1-b][1,3]oxazol-2-yl]piperazin-1-yl]-1-[4-(trifluoromethyl)phenyl]methanimine Chemical compound C1CN([C@]2(OC3=NC(=CN3C2)[N+]([O-])=O)C)CCN1N=CC1=CC=C(C(F)(F)F)C=C1 NTTYISLFBKCWJN-KRWDZBQOSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005933 neopentyloxycarbonyl group Chemical group 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 150000002916 oxazoles Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 125000005930 sec-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940072172 tetracycline antibiotic Drugs 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004784 trichloromethoxy group Chemical group ClC(O*)(Cl)Cl 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-298259 | 2002-10-11 | ||
| JP2002298259 | 2002-10-11 | ||
| PCT/JP2003/013070 WO2004033463A1 (ja) | 2002-10-11 | 2003-10-10 | ２，３−ジヒドロ−６−ニトロイミダゾ[２，１−ｂ]オキサゾール化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2497569A1 CA2497569A1 (en) | 2004-04-22 |
| CA2497569C true CA2497569C (en) | 2011-05-24 |
Family
ID=32089299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2497569A Expired - Lifetime CA2497569C (en) | 2002-10-11 | 2003-10-10 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound |
Country Status (26)
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002036587A2 (en) | 2000-11-01 | 2002-05-10 | Cor Therapeutics, Inc. | Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides |
| KR100655670B1 (ko) * | 2002-10-15 | 2007-02-28 | 오쓰까 세이야꾸 가부시키가이샤 | 1-치환된 4-니트로이미다졸 화합물 및 이의 제조 방법 |
| RU2365593C2 (ru) | 2003-10-31 | 2009-08-27 | Оцука Фармасьютикал Ко., Лтд. | ПРОИЗВОДНЫЕ 2,3-ДИГИДРО-6-НИТРОИМИДАЗО [2,1-b] ОКСАЗОЛА ДЛЯ ЛЕЧЕНИЯ ТУБЕРКУЛЕЗА |
| JP4761756B2 (ja) * | 2003-10-31 | 2011-08-31 | 大塚製薬株式会社 | ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物 |
| TWI300409B (en) | 2004-02-18 | 2008-09-01 | Otsuka Pharma Co Ltd | Method for producing 4-nitroimidazole compound |
| CN1938292B (zh) | 2004-03-31 | 2011-10-05 | 日本曹达株式会社 | 环胺化合物和有害生物防除剂 |
| JP4787529B2 (ja) * | 2004-04-09 | 2011-10-05 | 大塚製薬株式会社 | 医薬組成物 |
| JP4789966B2 (ja) * | 2004-04-09 | 2011-10-12 | 大塚製薬株式会社 | 医薬組成物 |
| ES2337728T3 (es) * | 2005-06-20 | 2010-04-28 | Schering Corporation | Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3. |
| PT1906926E (pt) * | 2005-07-28 | 2011-01-26 | Otsuka Pharma Co Ltd | Composição farmacêutica que contém derivados de 2,3-di-hidro-6-nitroimidazo[2,1-b]oxazole |
| TWI368509B (en) * | 2005-10-05 | 2012-07-21 | Otsuka Pharma Co Ltd | Antituberculous therapeutic drugs and kit containing the same |
| JP5105818B2 (ja) * | 2005-10-05 | 2012-12-26 | 大塚製薬株式会社 | 医薬組成物 |
| US8338607B2 (en) | 2005-10-06 | 2012-12-25 | Nippon Soda Co., Ltd. | Cyclic amine compounds and agents for pest control |
| TW200800268A (en) * | 2005-11-04 | 2008-01-01 | Otsuka Pharma Co Ltd | Medicinal composition showing improved drug absorbability |
| EP1968961A2 (en) * | 2005-12-21 | 2008-09-17 | Decode Genetics EHF | Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation |
| EP1986637A1 (en) * | 2006-02-13 | 2008-11-05 | Laboratoires Serono SA | Sulfonamide derivatives for the treatment of bacterial infections |
| JP2007297305A (ja) * | 2006-04-28 | 2007-11-15 | Daiso Co Ltd | Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法 |
| CA2678577A1 (en) * | 2007-02-26 | 2008-09-04 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| AR070301A1 (es) | 2007-05-08 | 2010-03-31 | Otsuka Pharma Co Ltd | Compuesto epoxi y metodo para producir el mismo |
| JP5470557B2 (ja) * | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| PE20090595A1 (es) * | 2007-08-15 | 2009-06-06 | Glaxo Group Ltd | Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1 |
| JP2011500634A (ja) * | 2007-10-16 | 2011-01-06 | グラクソ グループ リミテッド | 炎症性疾患およびアレルギー性疾患の治療に用いるキノリン誘導体 |
| AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| US8440658B2 (en) | 2007-12-11 | 2013-05-14 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| WO2009094169A1 (en) | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP5734666B2 (ja) * | 2008-02-11 | 2015-06-17 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤 |
| JP5730021B2 (ja) * | 2008-02-15 | 2015-06-03 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の阻害剤としてのシクロアルキルラクタム誘導体 |
| US20110105504A1 (en) * | 2008-03-18 | 2011-05-05 | Vitae Pharmaceuticals ,Inc. | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 |
| WO2009120789A1 (en) * | 2008-03-26 | 2009-10-01 | Global Alliance For Tb Drug Development | Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones |
| CL2009001058A1 (es) | 2008-05-01 | 2010-09-10 | Vitae Pharmaceuticals Inc | Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras. |
| WO2009134384A1 (en) * | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2300461B1 (en) * | 2008-05-01 | 2013-04-17 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| WO2009134387A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| KR20110050459A (ko) | 2008-07-25 | 2011-05-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| CA2729998A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
| CN102186833A (zh) * | 2008-08-18 | 2011-09-14 | 耶鲁大学 | Mif调节剂 |
| US8558005B2 (en) | 2008-08-21 | 2013-10-15 | Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik | Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof |
| WO2010143007A1 (en) * | 2009-06-10 | 2010-12-16 | Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik | Method for the production of 2-halogeno-4-nitroimidazole |
| US8637505B2 (en) | 2009-02-04 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
| KR20120061771A (ko) * | 2009-04-30 | 2012-06-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| MA33216B1 (fr) | 2009-04-30 | 2012-04-02 | Boehringer Ingelheim Int | Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1 |
| EP2440537A1 (en) | 2009-06-11 | 2012-04-18 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| JP5749263B2 (ja) | 2009-07-01 | 2015-07-15 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター |
| EP2459570B1 (en) * | 2009-07-31 | 2014-12-24 | Global Alliance For Tb Drug Development | Nitroimidazooxazine analogues and their uses |
| KR101746482B1 (ko) * | 2009-07-31 | 2017-06-27 | 글로벌 알리앙스 포 티비 드럭 디벨롭먼트 | 니트로이미다조옥사진 및 항결핵 치료요법에서의 이의 용도 |
| US9198913B2 (en) | 2009-07-31 | 2015-12-01 | Global Alliance For Tb Drug Development | Nitroimidazooxazines and their uses in anti-tubercular therapy |
| EP2495563A4 (en) | 2009-10-26 | 2013-04-10 | Fujifilm Ri Pharma Co Ltd | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES |
| TW201200523A (en) * | 2010-01-29 | 2012-01-01 | Otsuka Pharma Co Ltd | Synthetic intermediate of oxazole compound and method for producing the same |
| GB201012209D0 (en) * | 2010-05-31 | 2010-09-08 | Ge Healthcare Ltd | In vivo imaging agent |
| EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための１１−β−ＨＳＤ１のインヒビターとしてのアザスピロヘキサノン |
| AU2011325286B2 (en) | 2010-11-02 | 2015-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| US9051333B2 (en) | 2011-04-15 | 2015-06-09 | Otsuka Pharmaceutical Co., Ltd. | 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides |
| JP2015006994A (ja) * | 2011-10-28 | 2015-01-15 | 大正製薬株式会社 | ジヒドロイミダゾオキサゾール誘導体 |
| WO2014014845A1 (en) | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
| FR3000064A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes |
| EP3052503B1 (en) * | 2013-10-04 | 2018-10-24 | Council of Scientific & Industrial Research | 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles and a process for the preparation thereof |
| CN103524492A (zh) * | 2013-10-23 | 2014-01-22 | 中国药科大学 | 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途 |
| TWI687409B (zh) | 2014-08-28 | 2020-03-11 | 日商大塚製藥股份有限公司 | 稠合雜環化合物 |
| WO2016063298A1 (en) * | 2014-10-21 | 2016-04-28 | Council Of Scientific & Industrial Research | Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof |
| CN105732659B (zh) * | 2014-12-12 | 2019-07-16 | 上海阳帆医药科技有限公司 | 硝基咪唑类化合物及其制备方法和在制药中的用途 |
| MX2017009810A (es) * | 2015-01-29 | 2018-11-09 | Medshine Discovery Inc | Derivado de nitroimidazol contra tuberculosis pulmonar. |
| EP3275862B1 (en) | 2015-03-27 | 2020-08-12 | Otsuka Pharmaceutical Co., Ltd. | Method for producing 1-(4-hydroxyphenyl)-4-(4-trifluoromethoxyphenoxy)piperidine or salt thereof |
| CN106317072B (zh) * | 2015-06-17 | 2020-03-17 | 盟科医药技术(上海)有限公司 | 用于分枝杆菌感染治疗的杂环化合物及其应用 |
| EP3421454B9 (en) | 2016-02-26 | 2023-08-09 | Otsuka Pharmaceutical Co., Ltd. | Piperidine derivative |
| CN105859628B (zh) * | 2016-04-19 | 2018-08-07 | 清远职业技术学院 | 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用 |
| CN109496214B (zh) * | 2016-07-22 | 2024-09-10 | 成都嘉葆药银医药科技有限公司 | 一种硝基咪唑类化合物的晶型、盐型及其制备方法 |
| CA3072838A1 (en) * | 2017-08-16 | 2019-02-21 | Glaxosmithkline Intellectual Property Development Limited | Novel compounds |
| US20210251902A1 (en) | 2018-06-11 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Delamanid-containing composition |
| CN109705022A (zh) * | 2018-12-28 | 2019-05-03 | 上海彩迩文生化科技有限公司 | 一种芳香胺中间体的制备方法 |
| CN112300192B (zh) * | 2019-08-02 | 2023-08-11 | 南京长澳医药科技有限公司 | 硝基咪唑类化合物及其制备方法和用途 |
| CN110483549B (zh) * | 2019-08-30 | 2021-03-05 | 沈阳药科大学 | 一种硝基咪唑吡喃类抗结核药物的制备方法 |
| CN110615800A (zh) * | 2019-10-16 | 2019-12-27 | 李丽丽 | 硝基咪唑类化合物及其制备方法和用途 |
| CN112156088B (zh) * | 2020-10-30 | 2021-08-31 | 健民药业集团股份有限公司 | 一种化合物在制备结核分枝杆菌抑制剂中的用途 |
| CN113603706A (zh) * | 2021-08-04 | 2021-11-05 | 深圳市泰力生物医药有限公司 | 德拉马尼的晶型、含有该晶型的活性药物和药物组合物 |
| JPWO2024024938A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2022-07-29 | 2024-02-01 | ||
| CN115368252B (zh) * | 2022-09-19 | 2024-01-12 | 西北农林科技大学 | 一种4-胺基酚类衍生物及应用 |
| CN116640106B (zh) * | 2023-05-11 | 2024-03-08 | 郑州大学 | 一种苯基哌嗪类化合物及其制备方法、应用 |
| CN119059990B (zh) * | 2024-11-01 | 2025-02-07 | 安徽昊帆生物有限公司 | 1-氨基甲酸叔丁酯哌嗪的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668127A (en) | 1995-06-26 | 1997-09-16 | Pathogenesis Corporation | Nitroimidazole antibacterial compounds and methods of use thereof |
-
2003
- 2003-10-09 AR ARP030103673A patent/AR041198A1/es active IP Right Grant
- 2003-10-09 TW TW092128165A patent/TWI347946B/zh not_active IP Right Cessation
- 2003-10-10 PL PL376157A patent/PL217919B1/pl unknown
- 2003-10-10 KR KR1020057004567A patent/KR100723847B1/ko not_active Expired - Lifetime
- 2003-10-10 BR BRPI0314344A patent/BRPI0314344B8/pt not_active IP Right Cessation
- 2003-10-10 CN CN201110416170.4A patent/CN102532162B/zh not_active Expired - Lifetime
- 2003-10-10 UA UAA200504391A patent/UA83200C2/ru unknown
- 2003-10-10 EP EP12193820.3A patent/EP2570418A3/en not_active Withdrawn
- 2003-10-10 DK DK03754085.3T patent/DK1555267T3/da active
- 2003-10-10 WO PCT/JP2003/013070 patent/WO2004033463A1/ja active Application Filing
- 2003-10-10 SI SI200332254T patent/SI1555267T1/sl unknown
- 2003-10-10 MY MYPI20033866A patent/MY139244A/en unknown
- 2003-10-10 CN CNA2007100040367A patent/CN101172981A/zh active Pending
- 2003-10-10 EP EP03754085A patent/EP1555267B1/en not_active Expired - Lifetime
- 2003-10-10 PL PL404913A patent/PL404913A1/pl unknown
- 2003-10-10 US US10/530,429 patent/US7262212B2/en not_active Expired - Lifetime
- 2003-10-10 CA CA2497569A patent/CA2497569C/en not_active Expired - Lifetime
- 2003-10-10 AU AU2003272979A patent/AU2003272979B2/en not_active Expired
- 2003-10-10 CN CNA2007100040371A patent/CN101255170A/zh active Pending
- 2003-10-10 ES ES03754085T patent/ES2400179T3/es not_active Expired - Lifetime
- 2003-10-10 PT PT37540853T patent/PT1555267E/pt unknown
- 2003-10-10 CN CNB2003801017508A patent/CN100366624C/zh not_active Expired - Lifetime
- 2003-10-10 MX MXPA05003674A patent/MXPA05003674A/es active IP Right Grant
- 2003-10-10 RU RU2005114017A patent/RU2326121C3/ru active Protection Beyond IP Right Term
- 2003-10-10 PL PL409525A patent/PL409525A1/pl unknown
- 2003-10-14 JP JP2003353868A patent/JP4186065B2/ja not_active Expired - Lifetime
-
2005
- 2005-02-03 ZA ZA200501033A patent/ZA200501033B/en unknown
-
2012
- 2012-04-23 AR ARP120101394A patent/AR086485A2/es unknown
-
2013
- 2013-01-25 CY CY20131100076T patent/CY1113578T1/el unknown
- 2013-02-08 AR ARP130100408A patent/AR089950A2/es unknown
- 2013-07-15 AR ARP130102514 patent/AR091771A2/es not_active Application Discontinuation
-
2014
- 2014-08-13 LU LU92517C patent/LU92517I2/xx unknown
- 2014-08-14 HU HUS1400046C patent/HUS1400046I1/hu unknown
- 2014-09-09 BE BE2014C053C patent/BE2014C053I2/fr unknown
- 2014-09-11 FR FR14C0066C patent/FR14C0066I2/fr active Active
- 2014-09-24 CY CY2014041C patent/CY2014041I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2497569C (en) | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole compound | |
| JP4787529B2 (ja) | 医薬組成物 | |
| CA2539335A1 (en) | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | |
| EP3433234B1 (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| US20110301167A1 (en) | PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS | |
| EP3644990B1 (en) | 5-(pyridin-3-yl)oxazole allosteric modulators of the m4 muscarinic acetylcholine receptor | |
| EP3788043B1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | |
| JP5345174B2 (ja) | 医薬組成物 | |
| EP3684357B1 (en) | Heteroaryl allosteric modulators of nicotinic acetylcholine receptors | |
| JP4761756B2 (ja) | ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物 | |
| HK1120499A (en) | 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles | |
| HK1118543A (en) | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazoles | |
| HK1171018B (en) | 2,3-dihydro-6-nitroimidazo (2, 1-b) oxazoles | |
| HK1085463B (en) | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazoles | |
| HK40070885A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| HK1259808B (en) | Allosteric modulators of nicotinic acetylcholine receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20231010 |